Xwpharma Ltd.

Jia-ning Xiang

Daniel M Canafax

William W Xiang

Sami Karaborni

Wai-Si Eng

Xuesong Xu

Xianbo Liu

Yi Feng

Hao-Wei Shih

James Tien

Norbert Pollinger

Stefanie Thiel

Xuan Zhang

Dezheng Ning

Zude Qi

Xiaoming Wu

Nicolas D Kirkland

Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Modified release compositions of a gamma-hydroxybutyric acid derivative

Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.

Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Controlled release granulations of water-soluble active pharmaceutical ingredients

Nuclear transport modulators are disclosed. The compounds can inhibit nuclear transporters such as the exportin-1 transporter. The compounds and pharmaceutical compositions comprising the compounds can be used to treat neurological diseases and cancer.

Compounds as nuclear transport modulators and uses thereof

Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.

Ketamine derivatives and compositions thereof

The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.

Compounds as neuronal histamine receptor-3 antagonists and uses thereof

The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

Methods of synthesizing 4-valyloxybutyric acid

Modified release compositions of a GAMMA-hydroxybutyric acid derivative

The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).

Compounds as neurokinin-1 receptor antagonists and uses thereof

Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.

Growing community of inventors

FREMONT, CA, United States of America

Jia-ning Xiang